Overview

Fenofibrate in Dyslipidemia and Metformin-Controlled Diabetes

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The primary objective was to assess the effect of 3-month treatment of low and standard doses of fenofibrate in combination with stable dose of metformin on fasting triglycerides levels in patients with type 2 diabetes and dyslipidemia.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Solvay Pharmaceuticals
Treatments:
Fenofibrate
Metformin